CAMP
CAMP4 THERAPEUTICS CORPORATION (NASDAQ)
Healthcare — Biotechnology
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Price History
Fundamentals
| Market Cap | $225.36M |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.57 |
| EPS (TTM) | $-2.35 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | 50.80% |
| ROE | -209.28% |
| Debt/Equity | 6.87 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $8.58 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 50.0 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $7.75 |
| 52-Week Low | $1.32 |
| 50-Day Avg | $4.26 |
| 200-Day Avg | $4.33 |
| Avg Volume | 184.4K |
| Volume | 75.1K |
Performance Analysis
BULLISHCAMP shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:01 UTC
Back to Screener Export Report